Neurohormonal Therapy in Patients With Transthyretin Cardiac Amyloidosis
Daniel Enríquez-Vázquez, Milena Antúnez-Ballesteros, Gonzalo Barge-Caballero, María Jesús Paniagua-Martín, María Padilla-Bautista, Miguel González-Montes, David Couto-Mallón, José Manuel Vázquez-Rodríguez, Eduardo Barge-Caballero, María Generosa Crespo-Leiro · 2026
Read Neurohormonal Therapy in Patients With Transthyretin Cardiac Amyloidosis by Daniel Enríquez-Vázquez, Milena Antúnez-Ballesteros, Gonzalo Barge-Caballero, María Jesús Paniagua-Martín, María Padilla-Bautista, Miguel González-Montes, David Couto-Mallón, José Manuel Vázquez-Rodríguez, Eduardo Barge-Caballero, María Generosa Crespo-Leiro (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13616545.txt.
Description
Daniel Enriquez-Vazquez and co-authors report three heart patients whose weak hearts grew strong again on standard drug therapy, in a 2026 paper. The patients had a stiff heart disease from amyloid build up, a setting where heart failure drugs are often feared as poorly tolerated and the weak pump is seen as fixed.
All three began with pumping strength at or below 35 percent. Careful dose raising of guideline drugs lifted each to at least 50 percent, with clear clinical gains. That recovery then let them start a disease specific drug approved only above that line in their country. The authors urge case by case trials of the standard drugs.
Catalog record
| CREATOR | Daniel Enríquez-Vázquez, Milena Antúnez-Ballesteros, Gonzalo Barge-Caballero, María Jesús Paniagua-Martín, María Padilla-Bautista, Miguel González-Montes, David Couto-Mallón, José Manuel Vázquez-Rodríguez, Eduardo Barge-Caballero, María Generosa Crespo-Leiro |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |